The likely royalty stream to BTA should increase to ~$120M pa as GSK ramps up production, or ~90cps. Combined with the dual relenza molecule in advanced testing, the current share price looks a touch underdone. Surely within a year or less the likely fast-tracked license deals, perhaps $150M penalty payment from an obviously derelict GSK, the existing FluOIA diagnostic test and pipeline projects should make the true value of BTA closer to $25 than $1.
On a personal note, hope you can (also) get some relenza for personal use (it is still possible if you know where to look).
- Forums
- ASX - By Stock
- BTA
- medium-term valuation
medium-term valuation
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online